Table 3.
Comparison of the levels of FGF21 and FGF23 between controls and patients before and after treatment, including differentiation regarding BMI-class. FGF21and FGF23 concentrations given in pg/mL.
| Controls | Patients | BMI I | BMI II | BMI III | |
|---|---|---|---|---|---|
| FGF 21 | |||||
| Before | 4.75 (0.42–63.9) | 19.9 (0.42–1993) * | 9.6 (1.12–699) * # | 9.6 (2.49–197) * # | 28.9 (0.42–1993) * # |
| After | 12 (2–11507) * | 12.8 (4.15–11507) * | 9.6 (2–50.9) * | 13.6 (3.02–205) * | |
| FGF 23 | |||||
| Before | 1.32 (0.06–7.38) | 1.85 (0.06–10.4) | 3.21 (1.43–10.4) * # | 1.21 (0.12–2.8) * # | 2.09 (0.06–7.72) * # |
| After | 1.97 (0.19–8.06) | 2.29 (0.19–6.71) | 1.44 (0.34–6.38) | 2.28 (0.89–8.06) |
* statistical significances with p < 0.05 between Controls and Patients groups. # statistical significances with p < 0.05 between BMI-subgroups.